Jefferies lists 6 factors that will shape CRDMO winners; Divi’s Labs, Sai Life, Laurus, Anthem among stocks to watch
Divi's Laboratories set out an expansion in a quarterly results development.
· Economic Times Markets, ET Stocks
India's CRDMO sector is on the brink of expansion, backed by solid partnerships with major pharmaceutical players and comprehensive capabilities. Jefferies emphasizes the critical role of specialized manufacturing skills and a strong project pipeline for achieving success. With Divi's Laboratories and Sai Life Sciences excelling in these domains, there is potential for notable earnings growth.
The analysis
Against that, the stock is -0.7% on the day at ₹9,278.50, and has returned +33.0% over three months. It sits 4% below its 52-week high. The pharma & healthcare sector has moved -2.4% over the same period, so Divi's Laboratories is running 35.4 points ahead of its peers.
For Divi's Laboratories, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- The company directly in focus is DIVISLAB.
- Sector exposure: Pharma & Healthcare.
- The immediate tone of coverage reads positive.
In this story
Related coverage
BT BIG STORY: India Inc is more confident about Q3, but unwilling to hire or invest
Q2 Results Live: Tata Elxsi Rises 3% Ahead Of Earnings; ICICI Prudential Life Insurance, Anand Rathi Among Stocks In Focus
Q2 results today: Hero Motors, Tata Elxsi, 20 others to report earnings
'Be hungry like Samsung': Vedanta's Anil Agarwal shares S. Korean firm's growth story as it projects $80 bn in Q3 profit
Kolte-Patil Developers Q2 sales bookings rise 52% to record ₹1,019 crore